PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $264,866 | -42.7% | 37,096 | -32.3% | 0.00% | 0.0% |
| Q2 2022 | $462,000 | +40.0% | 54,769 | +124.9% | 0.00% | 0.0% |
| Q1 2022 | $330,000 | -47.8% | 24,352 | -24.3% | 0.00% | 0.0% |
| Q4 2021 | $632,000 | -37.2% | 32,165 | +8.2% | 0.00% | -80.0% |
| Q2 2021 | $1,007,000 | -76.5% | 29,731 | -73.9% | 0.01% | -75.0% |
| Q1 2021 | $4,278,000 | +8.6% | 113,885 | -4.0% | 0.02% | -4.8% |
| Q4 2020 | $3,941,000 | – | 118,649 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |